دورية أكاديمية
أعرض في EDS

PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases.

التفاصيل البيبلوغرافية
العنوان: PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases.
المؤلفون: Ferrucci V; Department of Molecular Medicine and Medical Biotechnology, DMMBM, University of Naples, Federico II, Via Pansini 5, 80131, Naples, Italy.; CEINGE Biotecnologie Avanzate 'Franco Salvatore', Via Gaetano Salvatore 486, 80145, Naples, Italy., Lomada S; Experimental Pharmacology Mannheim, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany.; DZHK, German Center for Cardiovascular Research, Partner Site Heidelberg/Mannheim, 68167, Mannheim, Germany., Wieland T; Experimental Pharmacology Mannheim, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, 68167, Mannheim, Germany. thomas.wieland@medma.uni-heidelberg.de.; DZHK, German Center for Cardiovascular Research, Partner Site Heidelberg/Mannheim, 68167, Mannheim, Germany. thomas.wieland@medma.uni-heidelberg.de.; Medical Faculty Mannheim, Ludolf Krehl-Str. 13-17, 68167, Mannheim, Germany. thomas.wieland@medma.uni-heidelberg.de., Zollo M; Department of Molecular Medicine and Medical Biotechnology, DMMBM, University of Naples, Federico II, Via Pansini 5, 80131, Naples, Italy. massimo.zollo@unina.it.; CEINGE Biotecnologie Avanzate 'Franco Salvatore', Via Gaetano Salvatore 486, 80145, Naples, Italy. massimo.zollo@unina.it.; DAI Medicina di Laboratorio e Trasfusionale, 'AOU' Federico II Policlinico, 80131, Naples, Italy. massimo.zollo@unina.it.
المصدر: Cancer metastasis reviews [Cancer Metastasis Rev] 2024 Jun; Vol. 43 (2), pp. 755-775. Date of Electronic Publication: 2024 Jan 05.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8605731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7233 (Electronic) Linking ISSN: 01677659 NLM ISO Abbreviation: Cancer Metastasis Rev Subsets: MEDLINE
أسماء مطبوعة: Publication: Dordrecht, The Netherlands ; Boston, MA : Kluwer Academic
Original Publication: The Hague ; Boston : M. Nijhoff, c1982-
مواضيع طبية MeSH: Energy Metabolism* , Neoplasms*/pathology , Neoplasms*/metabolism , Signal Transduction* , Neoplasm Metastasis* , NM23 Nucleoside Diphosphate Kinases*/metabolism, Humans ; Animals ; Nucleoside-Diphosphate Kinase/metabolism ; Acid Anhydride Hydrolases/metabolism ; Tumor Microenvironment ; Phosphoric Monoester Hydrolases
مستخلص: We describe here the molecular basis of the complex formation of PRUNE1 with the tumor metastasis suppressors NME1 and NME2, two isoforms appertaining to the nucleoside diphosphate kinase (NDPK) enzyme family, and how this complex regulates signaling the immune system and energy metabolism, thereby shaping the tumor microenvironment (TME). Disrupting the interaction between NME1/2 and PRUNE1, as suggested, holds the potential to be an excellent therapeutic target for the treatment of cancer and the inhibition of metastasis dissemination. Furthermore, we postulate an interaction and regulation of the other Class I NME proteins, NME3 and NME4 proteins, with PRUNE1 and discuss potential functions. Class I NME1-4 proteins are NTP/NDP transphosphorylases required for balancing the intracellular pools of nucleotide diphosphates and triphosphates. They regulate different cellular functions by interacting with a large variety of other proteins, and in cancer and metastasis processes, they can exert pro- and anti-oncogenic properties depending on the cellular context. In this review, we therefore additionally discuss general aspects of class1 NME and PRUNE1 molecular structures as well as their posttranslational modifications and subcellular localization. The current knowledge on the contributions of PRUNE1 as well as NME proteins to signaling cascades is summarized with a special regard to cancer and metastasis.
(© 2024. The Author(s).)
References: J Biol Chem. 1996 Oct 11;271(41):25107-16. (PMID: 8810265)
Cancer Sci. 2007 Aug;98(8):1198-205. (PMID: 17532757)
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9000-5. (PMID: 9256424)
Br J Haematol. 2023 Nov;203(4):599-613. (PMID: 37666675)
Nature. 2021 Dec;600(7890):720-726. (PMID: 34880500)
Circ Res. 2007 Apr 27;100(8):1191-9. (PMID: 17363702)
Cancer Metastasis Rev. 2012 Dec;31(3-4):593-603. (PMID: 22706779)
Curr Biol. 2003 Aug 19;13(16):1356-64. (PMID: 12932319)
Clin Exp Metastasis. 2008;25(2):131-8. (PMID: 18058029)
Nat Rev Immunol. 2020 May;20(5):294-307. (PMID: 31988391)
Antioxidants (Basel). 2022 Jul 14;11(7):. (PMID: 35883853)
Cells. 2021 Mar 28;10(4):. (PMID: 33800665)
J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):72-81. (PMID: 17964137)
Int J Mol Sci. 2023 Sep 08;24(18):. (PMID: 37762163)
Cancer Lett. 2020 Feb 28;471:125-134. (PMID: 31830561)
Nat Rev Mol Cell Biol. 2019 Jul;20(7):436-450. (PMID: 30976106)
Science. 2014 Jun 27;344(6191):1510-5. (PMID: 24970086)
J Phys Chem B. 2022 Sep 1;126(34):6372-6383. (PMID: 35976160)
Naunyn Schmiedebergs Arch Pharmacol. 2007 Feb;374(5-6):373-83. (PMID: 17200862)
Clin Cancer Res. 2005 Jan 1;11(1):199-205. (PMID: 15671547)
Nature. 2021 Mar;591(7851):645-651. (PMID: 33589820)
Sci Rep. 2013;3:1351. (PMID: 23448979)
Cancer Res. 2019 Sep 15;79(18):4689-4702. (PMID: 31311812)
Mol Cell. 2001 Nov;8(5):983-93. (PMID: 11741534)
Mol Biol Cell. 2006 Jan;17(1):146-54. (PMID: 16251351)
J Biol Chem. 2006 Nov 10;281(45):33830-4. (PMID: 16990267)
Oncotarget. 2014 Jul 30;5(14):5736-49. (PMID: 25026278)
Biochem Biophys Res Commun. 2007 May 4;356(2):348-53. (PMID: 17335772)
Mol Syst Biol. 2011 Oct 11;7:539. (PMID: 21988835)
Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):189-97. (PMID: 25234227)
BMC Biol. 2021 Oct 21;19(1):228. (PMID: 34674701)
Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):175-87. (PMID: 25366701)
J Biol Chem. 1997 Jun 20;272(25):15599-602. (PMID: 9188446)
Neurochem Res. 2019 Oct;44(10):2346-2359. (PMID: 30903449)
FEBS J. 2018 Aug;285(15):2856-2868. (PMID: 29863788)
Front Oncol. 2023 Feb 02;13:1103149. (PMID: 36816959)
J Hematol Oncol. 2022 Sep 17;15(1):135. (PMID: 36115986)
J Bioenerg Biomembr. 2006 Aug;38(3-4):233-46. (PMID: 17033939)
Lab Invest. 2018 May;98(5):571-581. (PMID: 29449633)
Naunyn Schmiedebergs Arch Pharmacol. 2011 Oct;384(4-5):373-81. (PMID: 21484438)
J Biol Chem. 2000 May 12;275(19):14264-72. (PMID: 10799505)
Front Immunol. 2021 Feb 24;12:613492. (PMID: 33732237)
Lab Invest. 2018 Feb;98(2):219-227. (PMID: 28991262)
J Bioenerg Biomembr. 2000 Jun;32(3):277-84. (PMID: 11768311)
Mol Pharmacol. 1992 Nov;42(5):731-5. (PMID: 1331759)
Int J Cancer. 2016 Aug 15;139(4):812-23. (PMID: 27037526)
Oncogene. 2007 May 14;26(22):3113-21. (PMID: 17496910)
Cancer Cell. 2018 Mar 12;33(3):480-494.e7. (PMID: 29533786)
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010 Dec;27(6):1332-5. (PMID: 21374989)
Biochem Biophys Res Commun. 1990 Apr 16;168(1):99-106. (PMID: 2158321)
Cell. 2015 Jul 2;162(1):198-210. (PMID: 26140597)
Oncol Lett. 2017 Aug;14(2):2475-2482. (PMID: 28781685)
Nature. 2014 Sep 25;513(7519):559-63. (PMID: 25043024)
FEBS Lett. 1989 Mar 13;245(1-2):189-93. (PMID: 2494072)
J Biol Chem. 1997 Feb 28;272(9):5525-32. (PMID: 9038158)
Trends Biochem Sci. 2016 Mar;41(3):211-218. (PMID: 26778478)
Nat Metab. 2020 Feb;2(2):132-141. (PMID: 32694690)
Breast Cancer Res Treat. 2014 Nov;148(1):99-106. (PMID: 25257727)
Cancer Res. 2016 Sep 15;76(18):5201-8. (PMID: 27587539)
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. (PMID: 34620838)
Semin Cancer Biol. 2012 Jun;22(3):234-49. (PMID: 22484561)
Biochemistry. 2008 Sep 9;47(36):9707-13. (PMID: 18700747)
Structure. 1995 Dec 15;3(12):1307-14. (PMID: 8747457)
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4385-90. (PMID: 11274357)
J Biochem. 2010 Aug;148(2):149-55. (PMID: 20403806)
Mol Cell. 2022 Feb 3;82(3):696-708.e4. (PMID: 35090599)
J Biol Chem. 1991 May 15;266(14):8784-9. (PMID: 1851158)
Front Oncol. 2022 Dec 20;12:1081712. (PMID: 36605449)
Nucleic Acids Res. 2014 Sep;42(15):9602-11. (PMID: 25081206)
FEBS J. 2018 Feb;285(4):700-716. (PMID: 29055087)
Nature. 1991 Oct 3;353(6343):437-40. (PMID: 1654526)
Oncol Rep. 2016 Jun;35(6):3445-52. (PMID: 27109060)
Immunity. 2016 Nov 15;45(5):1122-1134. (PMID: 27851913)
Front Oncol. 2017 Apr 12;7:68. (PMID: 28447025)
Nature. 2018 Mar 29;555(7698):678-682. (PMID: 29562234)
Oncogene. 2010 Apr 22;29(16):2393-403. (PMID: 20154719)
Nat Cell Biol. 2016 Oct;18(10):1090-101. (PMID: 27617932)
FEBS Lett. 2019 Jan;593(1):80-87. (PMID: 30411342)
Br J Cancer. 2021 Jan;124(1):66-75. (PMID: 33262521)
Redox Biol. 2021 Aug;44:101978. (PMID: 33903070)
Lab Invest. 2018 Feb;98(2):164-174. (PMID: 29451272)
J Biol Chem. 2003 Feb 28;278(9):7227-33. (PMID: 12486122)
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14911-8. (PMID: 10611312)
Lab Invest. 2018 Feb;98(2):211-218. (PMID: 29058704)
Dev Cell. 2020 Jul 20;54(2):183-195. (PMID: 32640203)
J Biol Chem. 1995 Sep 15;270(37):21758-64. (PMID: 7665595)
Sci STKE. 2004 Sep 07;2004(250):RE13. (PMID: 15367757)
Int J Mol Sci. 2020 Sep 16;21(18):. (PMID: 32947863)
Nat Rev Immunol. 2004 Jul;4(7):541-52. (PMID: 15229473)
Nat Commun. 2019 Jan 14;10(1):201. (PMID: 30643150)
J Biol Chem. 2019 Jul 19;294(29):11062-11086. (PMID: 31171722)
Nat Immunol. 2021 Feb;22(2):205-215. (PMID: 33398183)
Ann Surg Oncol. 2009 May;16(5):1390-6. (PMID: 17896143)
Brain. 2017 Apr 1;140(4):940-952. (PMID: 28334956)
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2117013119. (PMID: 35259022)
Lab Invest. 2018 Feb;98(2):175-181. (PMID: 29083410)
J Clin Invest. 2013 Sep;123(9):3678-84. (PMID: 23999442)
Front Oncol. 2021 Oct 22;11:758146. (PMID: 34745995)
Cancer Res. 2010 Oct 1;70(19):7710-22. (PMID: 20841469)
Eur J Biochem. 2001 Apr;268(7):1972-81. (PMID: 11277919)
Proteins. 2002 Feb 15;46(3):340-2. (PMID: 11835509)
Mol Cancer Res. 2018 Jun;16(6):986-999. (PMID: 29523766)
Anticancer Res. 2018 Nov;38(11):6059-6068. (PMID: 30396920)
Q J Nucl Med Mol Imaging. 2017 Mar;61(1):95-101. (PMID: 27982543)
Oncogene. 2008 Mar 20;27(13):1853-64. (PMID: 17906697)
Cancer Cell. 2004 Feb;5(2):137-49. (PMID: 14998490)
Clin Exp Metastasis. 2012 Apr;29(4):381-95. (PMID: 22322279)
Nature. 2020 Jan;577(7792):706-710. (PMID: 31942072)
J Natl Cancer Inst. 2005 May 4;97(9):632-42. (PMID: 15870434)
Mol Cell Biochem. 2009 Sep;329(1-2):149-59. (PMID: 19390954)
J Proteome Res. 2023 Mar 3;22(3):977-989. (PMID: 36779422)
Cancer Cell. 2023 Mar 13;41(3):421-433. (PMID: 36801000)
J Biol Chem. 2014 Jun 20;289(25):17709-20. (PMID: 24811176)
J Biol Chem. 1998 Oct 16;273(42):27580-6. (PMID: 9765291)
Cancer Res. 2011 Apr 1;71(7):2466-75. (PMID: 21427357)
Sci Rep. 2016 May 25;6:26703. (PMID: 27222072)
Cancer Res. 2012 Aug 1;72(15):3709-14. (PMID: 22787121)
Biochem J. 2007 Apr 1;403(1):149-56. (PMID: 17155928)
J Bioenerg Biomembr. 2006 Aug;38(3-4):163-7. (PMID: 17039395)
Biochem J. 2000 Mar 15;346 Pt 3:623-30. (PMID: 10698688)
J Biol Chem. 2003 Feb 28;278(9):7220-6. (PMID: 12486123)
Biochem Biophys Res Commun. 2003 Jun 20;306(1):110-5. (PMID: 12788074)
J Natl Cancer Inst. 2005 Jun 1;97(11):836-45. (PMID: 15928304)
Cancer Metastasis Rev. 2023 Dec;42(4):1155-1167. (PMID: 37353690)
Front Immunol. 2020 Jan 21;10:3038. (PMID: 32038612)
Sci Signal. 2021 Aug 03;14(694):. (PMID: 34344832)
Int J Mol Sci. 2021 Jan 09;22(2):. (PMID: 33435297)
Curr Biol. 2020 Aug 17;30(16):R921-R925. (PMID: 32810447)
Mol Cell Biochem. 2009 Sep;329(1-2):51-62. (PMID: 19387795)
Medicine (Baltimore). 2022 Nov 11;101(45):e31493. (PMID: 36397343)
Cell Death Differ. 2001 May;8(5):470-6. (PMID: 11423907)
Brain. 2018 May 1;141(5):1300-1319. (PMID: 29490009)
Biochem Biophys Res Commun. 2013 May 10;434(3):541-6. (PMID: 23583378)
Cell Commun Signal. 2020 Apr 7;18(1):59. (PMID: 32264958)
Nature. 1994 Aug 4;370(6488):335-6. (PMID: 8047138)
Mol Cell Biol. 2015 Mar;35(6):1001-13. (PMID: 25582197)
Sci Rep. 2018 Jul 19;8(1):10909. (PMID: 30026594)
Int J Mol Sci. 2020 Aug 14;21(16):. (PMID: 32823988)
Nat Cell Biol. 2002 Dec;4(12):929-36. (PMID: 12447393)
J Biol Chem. 2004 Aug 27;279(35):36621-4. (PMID: 15234968)
Chemistry. 2013 Sep 9;19(37):12217-20. (PMID: 23939913)
J Neurosci. 2019 Jul 31;39(31):6038-6048. (PMID: 31147524)
Transl Cancer Res. 2020 Oct;9(10):6369-6382. (PMID: 35117245)
Genetics. 1956 Jan;41(1):118-23. (PMID: 17247604)
Mol Cell Biol. 2004 May;24(10):4407-16. (PMID: 15121859)
Biochemistry. 2005 Dec 6;44(48):15774-86. (PMID: 16313181)
Cell Death Differ. 2016 Jul;23(7):1140-51. (PMID: 26742431)
J Bioenerg Biomembr. 2000 Jun;32(3):269-75. (PMID: 11768310)
Eur J Cancer Prev. 2013 Nov;22(6):512-22. (PMID: 23765094)
PLoS One. 2009 Nov 23;4(11):e7949. (PMID: 19956735)
EMBO Rep. 2022 Dec 6;23(12):e55076. (PMID: 36278516)
J Biol Chem. 2007 Apr 20;282(16):12075-96. (PMID: 17314099)
Biochem J. 2007 Oct 15;407(2):199-205. (PMID: 17655525)
Cell Metab. 2006 Mar;3(3):177-85. (PMID: 16517405)
Oncotarget. 2017 Dec 31;9(12):10185-10202. (PMID: 29535799)
Oncogenesis. 2021 Apr 30;10(4):34. (PMID: 33931587)
Gene. 2012 Nov 1;509(1):93-103. (PMID: 22967741)
Comput Struct Biotechnol J. 2018 Nov 22;17:1-13. (PMID: 30581539)
Int J Mol Sci. 2020 Jul 17;21(14):. (PMID: 32708927)
Nucleic Acids Res. 2003 Jul 1;31(13):3320-3. (PMID: 12824317)
Genetics. 1996 Dec;144(4):1589-600. (PMID: 8978047)
Cancer Res. 2011 Dec 1;71(23):7216-25. (PMID: 21987726)
Cell. 2016 Mar 24;165(1):153-164. (PMID: 26972053)
Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):257-69. (PMID: 25138575)
Cancer Biol Ther. 2010 Jun 15;9(12):1065-78. (PMID: 20448457)
J Biol Chem. 2008 Sep 19;283(38):26198-207. (PMID: 18635542)
FEBS Lett. 2020 Dec;594(24):4201-4232. (PMID: 33270228)
PLoS One. 2015 Oct 01;10(10):e0139616. (PMID: 26426123)
Biochemistry. 1994 Jan 18;33(2):459-67. (PMID: 8286376)
Int J Mol Sci. 2018 Oct 30;19(11):. (PMID: 30380757)
Nat Rev Immunol. 2019 Mar;19(3):184-197. (PMID: 30718831)
Biochem Biophys Res Commun. 2003 Jul 25;307(2):281-9. (PMID: 12859952)
J Mol Biol. 1995 Aug 25;251(4):574-87. (PMID: 7658474)
Lab Invest. 2018 Feb;98(2):248-257. (PMID: 29035383)
J Biol Chem. 2002 Aug 30;277(35):32389-99. (PMID: 12105213)
Circulation. 2017 Feb 28;135(9):881-897. (PMID: 27927712)
Mol Oncol. 2021 May;15(5):1376-1390. (PMID: 33274599)
PLoS One. 2023 Jul 7;18(7):e0288162. (PMID: 37418424)
iScience. 2020 Dec 13;24(1):101938. (PMID: 33426510)
Chem Rev. 2019 Dec 26;119(24):12337-12374. (PMID: 31738523)
J Biol Chem. 1993 Dec 5;268(34):25780-9. (PMID: 8245015)
Blood. 2019 May 16;133(20):2159-2167. (PMID: 30898857)
J Biol Chem. 1962 Oct;237:PC3306-PC3308. (PMID: 14014715)
Biochemistry. 2000 Aug 22;39(33):10090-7. (PMID: 10955997)
فهرسة مساهمة: Keywords: Energy metabolism; Exopolyphosphatase; Immune system; NME family; NMR structures; Nucleoside diphosphate kinase NDPK; PRUNE1; Tumor microenvironment
المشرفين على المادة: 0 (NM23 Nucleoside Diphosphate Kinases)
EC 2.7.4.6 (NME1 protein, human)
EC 3.1.3.2 (PRUNE1 protein, human)
EC 2.7.4.6 (Nucleoside-Diphosphate Kinase)
EC 3.6.- (Acid Anhydride Hydrolases)
EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
تواريخ الأحداث: Date Created: 20240105 Date Completed: 20240606 Latest Revision: 20240610
رمز التحديث: 20240611
مُعرف محوري في PubMed: PMC11156750
DOI: 10.1007/s10555-023-10165-4
PMID: 38180572
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7233
DOI:10.1007/s10555-023-10165-4